TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Prostatype Genomics AB
Closing information (x1000 NOK)
| Closing information | 2023/12 (consolidated) | 2022/12 | 2021/12 |
| Turnover |
1,374
|
646
|
10 |
| Financial expenses |
2,221
|
375
|
79 |
| Earnings before taxes |
-41,975
|
-27,514
|
-15,243 |
| EBITDA |
-37,859
|
-25,337
|
-15,077 |
| Total assets |
49,863
|
29,276
|
39,207 |
| Current assets |
26,248
|
13,403
|
21,050 |
| Current liabilities |
24,801
|
4,098
|
3,345 |
| Equity capital |
24,995
|
24,737
|
35,016 |
| - share capital |
7,261
|
1,298
|
883 |
| Employees (average) |
7
|
6
|
5 |
Financial ratios
| Fiscal year | 2023/12 (consolidated) | 2022/12 | 2021/12 |
| Solvency |
50.1%
|
84.5%
|
89.3% |
| Turnover per employee |
196
|
108
|
2 |
| Profit as a percentage of turnover |
-3054.9%
|
-4259.1%
|
-152430.0% |
| Return on assets (ROA) |
-79.7%
|
-92.7%
|
-38.7% |
| Current ratio |
105.8%
|
327.1%
|
629.3% |
| Return on equity (ROE) |
-167.9%
|
-111.2%
|
-43.5% |
| Change turnover | |||
| Change turnover % |
6730%
|
-99% | |
| Chg. No. of employees | |||
| Chg. No. of employees % |
20%
|
0% |
Total value of public sale
| Fiscal year | 2023/12 (consolidated) | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.